Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06882356 · ClinicalTrials.gov registry record · NA

The Glaucoma and Retinopathy Screening Study

A NA study of Glaucoma, sponsored by Massachusetts Eye and Ear Infirmary.

Recruiting
Registry status
NA
Development phase
2,000
Enrollment target
5
Study locations

NCT06882356: Recruiting NA study of Glaucoma, sponsored by Massachusetts Eye and Ear Infirmary.

NCT06882356 is a NA study of Glaucoma that is actively recruiting participants, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 2,000 participants, above the 889-participant average among 92 other Glaucoma trials with a reported enrollment target (125% higher). The trial reports 5 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06882356, a NA study of Glaucoma, is actively recruiting participants, sponsored by Massachusetts Eye and Ear Infirmary.

RECRUITING
Registry status
NA
Development phase
2,000 participants
Enrollment target
5
Study locations

Study Summary

The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma. Participants will: Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset

Primary Outcome

This primary outcome measure will assesses the proportion of participants who receive a glaucoma diagnosis in the combined DED and glaucoma screening group compared to the DED-only screening group. Glaucoma diagnosis in the intervention group is based on AI-assisted analysis of fundus photography, intraocular pressure, and virtual reality perimetry testing for confirmation.

Conditions Studied

Interventions

  • DEVICE AI-based glaucoma screening
  • DEVICE IOP measurement
  • DEVICE Virtual Reality Visual Field Testing

Study Locations (5)

Massachusetts

  • Brigham and Women's Primary Care Associates of Longwood - Boston
  • MGH Chelsea HealthCare Center - Chelsea
  • NSPG Lynn - Lynn
  • NSPG Salem - Salem
  • NSPG Saugus - Saugus

Trial Details

FieldValue
Enrollment Target 2,000 participants
Start Date 2025-07-16
Est. Completion 2030-09
Phase NA

What NCT06882356 shows while recruiting

NCT06882356 is an interventional study that assigns participants to a tested intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, above the 889-participant average among 92 other Glaucoma trials with a reported enrollment target (125% higher).

The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 3 interventions - of which AI-based glaucoma screening is the first listed.

NCT06882356 lists 5 locations in 1 state (Massachusetts).

Frequently Asked Questions

What is clinical trial NCT06882356 about?

NCT06882356 is a clinical study titled "The Glaucoma and Retinopathy Screening Study". The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma. Participants will: Have an image of their fundus (back of the ...

What is the current status of trial NCT06882356?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,000 participants. The study started on 2025-07-16. Estimated completion is 2030-09.

What conditions does trial NCT06882356 study?

This clinical trial studies the following conditions: Glaucoma.

What interventions are being tested in trial NCT06882356?

The interventions under investigation include: AI-based glaucoma screening (DEVICE), IOP measurement (DEVICE), Virtual Reality Visual Field Testing (DEVICE).

Who is sponsoring clinical trial NCT06882356?

This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06882356 being conducted?

This trial has 5 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06882356's enrollment target sits among peer trials

2,000 3rd of 92 higher than 90 of 92 other Glaucoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001465 · 2,000 participants

    Study of the Disease Process of Lymphangioleiomyomatosis

  • NCT00001595 · 2,000 participants

    An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

  • NCT00138931 · 2,000 participants

    Genetics of Cardiovascular and Neuromuscular Disease

  • NCT00288119 · 2,000 participants

    Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06882356, the US trial registry maintained by the National Library of Medicine. NCT06882356 (large enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.